Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
REDWOOD CITY, Calif., Feb. 01, 2016 -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at 8:00 AM ET at the Waldorf Astoria Hotel in New York City.
The presentation will be webcast live and may be accessed by visiting the “Events & Presentations” section of the Company's website at www.capnia.com. The webcast will also be available on the Company’s website for a limited period of time following the conference.
About Capnia
Capnia, Inc. is a diversified healthcare company that develops innovative diagnostics, devices and therapeutics addressing unmet medical needs. Capnia's lead commercial product, CoSense, is based on the Sensalyze™ Technology Platform. It is a portable, non-invasive device that rapidly and accurately measures carbon monoxide (CO) in exhaled breath. CoSense has 510(k) clearance for sale in the U.S. and has received CE Mark certification for sale in the European Union. CoSense is used for the monitoring of CO from internal sources (such as hemolysis, a dangerous condition in which red blood cells degrade rapidly), as well as external sources (such as CO poisoning and smoke inhalation). The initial target market is newborns with jaundice that are at risk for hemolysis, comprising approximately three million births in the U.S. and European Union. The Company's commercial, neonatology-focused product line also includes innovative pulmonary resuscitation solutions, including the NeoPIP™ Infant T-Piece Resuscitator and Universal T-Piece Circuit consumables. Capnia's proprietary therapeutic technology uses nasal, non-inhaled CO2 and is being evaluated to treat the symptoms of allergies, as well as the trigeminally-mediated pain conditions such as cluster headache, trigeminal neuralgia and migraine.
Investor Relations Contact: Michelle Carroll/Susie Kim Argot Partners (212) 600-1902 [email protected] [email protected]
